STOCK TITAN

Veru Inc. - $VERU STOCK NEWS

Welcome to our dedicated page for Veru news (Ticker: $VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Veru's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Veru's position in the market.

Rhea-AI Summary

Veru (NASDAQ: VERU), a biopharmaceutical company, announced that its CEO, Mitchell Steiner, M.D., will present at the Jefferies Global Healthcare Conference on June 5, 2024, from 11:00 am to 11:25 am ET. The presentation will focus on the Phase 2b clinical program of enobosarm. Enobosarm aims to augment fat loss and prevent muscle loss when combined with GLP-1 drugs for weight loss. A live webcast of the presentation will be available on Veru's website, with an archived version accessible post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
conferences
-
Rhea-AI Summary

Veru (NASDAQ: VERU) has announced the appointment of Dr. Steven B. Heymsfield as the Principal Investigator for its Phase 2b clinical trial of enobosarm, aimed at preserving muscle while enhancing fat loss in patients using GLP-1 RAs for weight loss.

Dr. Heymsfield is a renowned expert in body composition and obesity, with extensive experience in clinical research and over 600 peer-reviewed publications. The trial seeks to address the issue of muscle loss in weight loss treatments. Veru anticipates enrolling the trial quickly and expects data by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Veru, a biopharmaceutical company specializing in innovative medicine for oncology and viral-induced acute respiratory distress syndrome, will see its CEO, Dr. Mitchell Steiner, present a keynote at Biomed Israel 2024. The event, taking place May 21-23 in Tel Aviv, Israel, focuses on life science and technology advancements. Dr. Steiner's presentation, scheduled for May 22, will discuss the effects of GLP-1 receptor agonists on muscle loss and weight management, particularly in older sarcopenic obese patients. The session aims to explore how preserving muscle mass can enhance the effectiveness of weight loss drugs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.53%
Tags
none
Rhea-AI Summary

Veru Inc. reported fiscal 2024 second quarter financial results and provided updates on its Enobosarm high-quality weight loss clinical program. The Phase 2b clinical study of enobosarm in combination with semaglutide is actively enrolling. The company has formed a high-quality weight loss Scientific Advisory Board with five medical experts and will present at upcoming medical conferences. Veru Inc. aims to develop innovative medicines for weight loss, oncology, and respiratory distress syndrome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.27%
Tags
-
Rhea-AI Summary

Veru Inc. (NASDAQ: VERU) will present at the GLP-1 Based Therapeutics Summit in Philadelphia, discussing Enobosarm, a drug to avoid muscle loss and enhance weight loss quality. The presentation aims to address muscle loss issues in weight management and the potential benefits of combining Enobosarm with a GLP-1 RA. The event is scheduled for May 15-16, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.07%
Tags
conferences
-
Rhea-AI Summary

Veru Inc. (NASDAQ: VERU) will host a conference call and webcast on May 8, 2024, to discuss its fiscal 2024 second quarter financial results and provide a business update. The company focuses on developing innovative medicines for weight loss, oncology, and respiratory distress syndrome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.37%
Tags
conferences earnings
Rhea-AI Summary

Veru Inc. (NASDAQ: VERU) has enrolled the first patients in a Phase 2b clinical trial of enobosarm and semaglutide combination for high-quality weight loss. The study aims to preserve muscle mass during weight loss therapy, with topline data expected in the fourth quarter of 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8%
Tags
-
Rhea-AI Summary
Veru Inc. (NASDAQ: VERU) will present two late-breaking abstract presentations at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11, 2024. The presentations focus on Enobosarm, a potential weight loss medication that aims to reduce fat mass while preserving muscle in older patients with obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
conferences
-
Rhea-AI Summary
Veru Inc. (NASDAQ: VERU) filed its 2023 Form 10-K/A and Q1 2024 Form 10-Q, rescheduling the Annual Meeting of Shareholders to June 18, 2024. The company focuses on innovative medicines for weight loss, oncology, and respiratory distress syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
none
Rhea-AI Summary
Veru Inc. reschedules its 2024 Annual Meeting of Shareholders to allow time for reviewing restated financial statements. The company is in the process of restating historical financial statements, with expected filings by April 15, 2024. Research and development expenses were overestimated, leading to an extended cash runway for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.79%
Tags
none
Veru Inc.

Nasdaq:VERU

VERU Rankings

VERU Stock Data

162.49M
112.01M
14.11%
40.25%
6.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
MIAMI

About VERU

the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries